09:22 AM EST - HLS Therapeutics Inc. : Announces its financial results for the three months ended September 30, 2026. All amounts are in United States dollars unless otherwise stated. Q3 2026 revenue was $14.2 million, Adjusted EBITDA was $5.0 million and cash from operations was $1.8 million, compared to $13.5 million, $4.9 million and $2.5 million, respectively. HLS Therapeutics Inc.
shares T.HLS are trading unchanged at $4.19.
